Want to see COSM full AI Analyst Report?
COSM Stock Chart & Stats
$0.22
<$0.01(3.75%)
At close: 4:00 PM EDT
$0.22
<$0.01(3.75%)
Day’s Range― - ―
52-Week Range$0.16 - $1.26
Previous Close$0.2
Volume2.90M
Average Volume (3M)3.70M
Market Cap
$35.18M
Enterprise Value$25.04M
Total Cash (Recent Filing)$1.84M
Total Debt (Recent Filing)$15.98M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding100,633,770
10 Day Avg. Volume3,823,908
30 Day Avg. Volume3,696,368
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue0.34
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda-1.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$80.80M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth indicates continued demand for the company’s pharmaceutical and nutraceutical distribution activities. If maintained, rising revenue can improve operating leverage, broaden channel reach, and provide a larger base from which management can pursue eventual profitability.
Debt ReductionThe substantial reduction in debt improves financial flexibility and lowers balance-sheet pressure relative to earlier periods. Reduced leverage may help preserve capital for operations and growth, while making the company less exposed to financing strain if business conditions remain challenging.
Governance Continuity And Financing FlexibilityShareholder approval preserves management continuity while expanding the company’s available equity and incentive tools. These mechanisms could support fundraising, strategic execution, and employee alignment over the medium term, although their effectiveness depends on disciplined deployment.
Bears Say
Persistent UnprofitabilityRevenue growth has not translated into adequate profitability, with thin gross margins and substantial operating and net losses. This suggests the current distribution model has limited earnings resilience and may require significant cost improvement or better product economics to become sustainable.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is consuming cash rather than internally funding its activities. Continued burn can reduce financial flexibility and increase reliance on external financing or balance-sheet actions to sustain operations and pursue growth.
Potential Equity DilutionThe expanded equity toolkit may help fund the company, but issuing preferred or plan-related securities can dilute existing ownership and alter capital-structure economics. This risk is particularly relevant while losses and cash burn remain unresolved, because financing needs may persist.
Cosmos Holdings News
COSM FAQ
What was Cosmos Holdings Inc’s price range in the past 12 months?
Cosmos Holdings Inc lowest stock price was $0.16 and its highest was $1.25 in the past 12 months.
What is Cosmos Holdings Inc’s market cap?
Cosmos Holdings Inc’s market cap is $35.18M.
When is Cosmos Holdings Inc’s upcoming earnings report date?
Cosmos Holdings Inc’s upcoming earnings report date is Nov 17, 2026 which is in 34 days.
How were Cosmos Holdings Inc’s earnings last quarter?
Cosmos Holdings Inc released its earnings results on Aug 19, 2026. The company reported -$0.1 earnings per share for the quarter.
Is Cosmos Holdings Inc overvalued?
According to Wall Street analysts Cosmos Holdings Inc’s price is currently Overvalued.
Does Cosmos Holdings Inc pay dividends?
Cosmos Holdings Inc does not currently pay dividends.
What is Cosmos Holdings Inc’s EPS estimate?
Cosmos Holdings Inc’s EPS estimate is -0.06.
How many shares outstanding does Cosmos Holdings Inc have?
Cosmos Holdings Inc has 100,633,770 shares outstanding.
What happened to Cosmos Holdings Inc’s price movement after its last earnings report?
Cosmos Holdings Inc reported an EPS of -$0.1 in its last earnings report. Following the earnings report the stock price went up 9.845%.
Which hedge fund is a major shareholder of Cosmos Holdings Inc?
Currently, no hedge funds are holding shares in COSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cosmos Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
COSM Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth $207.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.54%
12-Months-Change
Fundamentals
Return on Equity
-118.89%
Trailing 12-Months
Asset Growth
-0.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cosmos Holdings Inc
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Technical Analysis
Ownership Overview
17.36% Insiders
0.30% Mutual Funds
0.04% Other Institutional Investors
82.00% Public Companies and
Individual Investors